Genomic aberrations as prognostic factors for time-limited Venclyxto, Venetoclax-based combinations

Genomic aberrations are established prognostic factors in chemoimmunotherapy of CLL but the role of these factors is less-well established for time limited treatment with venetoclax in combination with Rituximab, Obinutuzumab and Obinutuzumab and Ibrutinib. In this MEDtalk Eugen Tausch, MD, Department of Internal Medicine, University Hospital Ulm, Germany, presents the data from the CLL13/GAIA Trial where three time limited combination treatments with venetoclax are compared with chemoimmunotherapy. Co-primary endpoints were PFS and MRD.